Anthony J. Aldave, MD 

Ocunexus Therapeutics

Ocunexus Therapeutics

Role:               Site Principal Investigator

Duration:         10/1/21-9/30/26

Description:     A Phase 2, randomized, prospective, double-masked, vehicle-controlled study to assess the efficacy and safety of Nexagon® applied topically in subjects with corneal persistent epithelial defects (PED) resulting from severe ocular chemical and/or thermal injuries.

Oyster Point

Oyster Point Pharma, Inc.

Role:               Site Principal Investigator

Duration:         8/11/21-8/10/26

Description:     A Phase 2, Multicenter, Randomized, Controlled, Double-Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray in Subjects with Neurotrophic Keratopathy (the Olympia Study

DEKS

NIH/National Eye Institute

Role:               Site Principal Investigator

Duration:         05/01/21-04/30/26

Description:     Diabetes Endothelial Keratoplasty Study (DEKS): Impact of Diabetes on Corneal Transplant Success and Cell Loss

Eye Bank Association of America

Eye Bank Association of America

Role:               Principal Investigator

Duration:         07/01/21-06/30/22

Description:     EBAA Pilot Research Grant: Does COVID-19 vaccination increase the risk of corneal transplant rejection?

UCLA Faculty Grant

UCLA Faculty Research Grant

Role:               Principal Investigator

Duration:         07/01/21-06/30/22

Description:     Determining the impact of SLC4A11 deficiency on oxidative stress and assessing the therapeutic effect of SkQ1 treatment in SLC4A11-deficient cell-based models of corneal endothelial dystrophies

David Geffen School of Mediciine

UCLA Global Health Seed Grant

Role:               Principal Investigator

Duration:         06/01/21-05/31/22

Description:     Prospective clinical trial evaluating the usage of sterile preserved cornea tissue in treating infectious corneal perforation in Vietnam


Doug Chung, PhD

Knights Templar Logo

Knights Templar Eye Foundation Career Starter Grant

Role:               Principal Investigator

Duration:         07/01/21-06/30/22

Description:     Elucidating the role of SLC4A11 in Congenital Hereditary Endothelial Dystrophy


Wenlin Zhang, MD, PhD

ARVO Foundation for Eye Research logo

ARVO Foundation/EBAA EyeFind Research Grant

Role:               Principal Investigator

Duration:         07/01/21-06/30/22

Description:     Quantitative super-resolution localization of SLC4A11 variants in human corneal endothelium in its native environment